SESSION 1
NEUROPATHOLOGY OF MS – IS IT WHITE OR GREY?
Chair Nicole Schoeren-Wiemers (Basel, Switzerland)

09.10 Relevance of grey matter lesions for the pathogenesis of MS
Christine Stadelmann (Göttingen, Germany)

09.40 Mediators of neuronal damage in CNS autoimmune disease
Doron Merkler (Geneva, Switzerland)

10.10 Mechanisms of CNS remyelination
Catherine Lubetzki (Paris, France)

10.40 Coffee Break

SESSION 2
IMMUNOPATHOGENESIS OF MS – OF MICE AND MEN
Chair Burkhard Becher, (Zürich, Switzerland)

11.10 Microbial trigger of nervous system autoimmunity
Gurumoorthy Krishnamoorthy (Martinsried, Germany)

11.40 Antiviral Immune Responses in MS
Jan Lünemann (Zürich, Switzerland)

12.10 Checkpoints on the way to the brain: how pathogenic T cells invade the CNS
Alexander Flügel (Göttingen, Germany)

12.40 Lunch

SESSION 3
DO WE HAVE TOOLS FOR AN INDIVIDUALIZED PATIENT CARE?
Chair Tobias Derfuss, (Basel, Switzerland)

14.00 The new spectrum of NMO spectrum disorder: consequences for the therapeutical point of view
Jérôme De Seze (Strasbourg, France)

14.30 Individual treatment selection and treatment monitoring with MRI: are we there yet?
Till Sprenger (Basel, Switzerland)

15.00 What can biomarkers add?
Jens Kuhle (Basel, Switzerland)

15.30 Coffee Break

SESSION 4
TREATMENTS TODAY – FROM CLINICAL AND INDUSTRIAL PERSPECTIVE
Chair Ludwig Kappos, (Basel, Switzerland)

16.00 MS treatments: the best is yet to come?
Tobias Derfuss (Basel, Switzerland)

16.30 MS: complex trials in a brave new world
Erik Wallström (Basel, Switzerland)

17.00 Closing remarks
Ludwig Kappos, (Basel, Switzerland)